As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

Most shampoos do a decent job of cleaning the hair shaft. But if you keep dealing with flakes, an itchy scalp, or that persistent oily feel...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

A gap in science-backed skincare products in the Indian market prompted Shaily Mehrotra to start Fixderma, with an aim to solve common skin...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...

As far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

Quadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...

Mankind Pharma, guided by Ramesh and Rajeev Juneja, is a leading Indian pharmaceutical firm. The company focuses on mass-market drugs and h...

The portfolio of brands acquired focus on anti-infectives largely catering to the women's health and gynaecology segment, the spokesperson ...

"Samara Capital is bullish on this segment and 7-8 brands which are part of the anti-infective portfolio will be acquired as part of the de...